1.Therapeutic Observation of Contralateral Needling plus Point-toward-point Method for Hemifacial Spasm
Hongguo WANG ; Xiao CHEN ; Zihong CHEN
Shanghai Journal of Acupuncture and Moxibustion 2015;(12):1186-1187
ObjectiveTo observe the efficacy of contralateral needling plus point-toward-point method in treatinghemifacial spasm, and to seek the optimal treatment protocol by combining clinical data.MethodNinety-four patients with hemifacial spasm were randomized into a treatment group and a control group, 47 cases in each group. The control group was by acupuncture at the affected side, while the treatment group was by contralateral needling plus point-toward-point method. The therapeutic efficacy was analyzed by comparing the changes of symptoms and the recovery of the spastic facial tissues.ResultThe symptoms in the treatment group were effectively mitigated, and the effective rate was 97.9%, significantly higher than 83.0% in the control group (P<0.05).ConclusionContralateral needling plus point-toward-point method is significantly effective in treating hemifacial spasm, and it benefits the recovery of the facial muscle function.
2.The Causes and Treatment for Cerebrospinal Fluid Leak after Microsurgical Removal of Vestibular Schwannomas
Daofeng TIAN ; Hongguo WANG ; Qianxue CHEN
Journal of Chinese Physician 2001;0(10):-
Objective To explore the causes and treatment for cerebrospinal fluid(CSF) leak after microsurgical removal of vestibular schwannomas(VS) with the suboccipital retrosigmoid approach.Methods A retrospective study was accomplished on 258 patients with VS operated through the suboccipital retrosigmoidal approach from Jan 1994 to Aug 2003.After operation,cerebrospinal fluid rhinorrhea occurred in 19 cases and subcutaneous retroauricular CSF leak occurred in 5 cases.Results In 14 cases the CSF leak was stopped after treatment by external lumbar cerebrospinal fluid drainage(CELCFD).Six patients were operated again with sealing the internal acoustic meatus and the mastoid cells with fibrin glue and muscle.The patients were followed up for 14 months to 8 years after treatment,and there was no recurrence of CSF leak or delayed onset meningitis.Conclusion CSF leak was the common complication after vestibular schwannoma removal and the most common reason was the drilled posterior wall of the internal acoustic meatus with opening of the mastoid cells.The closure of petrous air cells was very important to prevent its postoperative CSF leak.Most of the patients were successfully treated by external lumbar cerebrospinal fluid drainage and only a few cases needed revision surgery.
3.Current fundraising for NRCMS and sustainable fundraising strategies
Xiaoling YAN ; Hongguo WANG ; Hongjing CHEN ; Shan WANG ; Keqin RAO
Chinese Journal of Hospital Administration 2013;29(4):285-288
Dynamic and sustainable fundraising strategies are the prerequisite for the long-term and stable development of the New Rural Cooperative Medical Scheme(NRCMS).The paper analyzed the current situation and problems of NRCMS' fundraising,and proposed the principles for designing a sustainable financing strategy of NRCMS,and then its fundraising strategy.First,clarification of its fundraising sources and rational division of the sharing ratio of the funding bodies (individuals contributions account for 20%of the per capita fundraising) ; second,linking fundraising levels with net per capita net income(5 % ~ 6 %) of peasants; third,expansion of the service scope and level coordinated within NRCM.
5.Prospective multicentre study of chemotherapeutic regimen containing pirarubicin on the treatment of relapsed or refractory acute myeloid leukemia in adults.
Feng CHEN ; Jingxia WANG ; Ming HOU ; Hongguo ZHAO ; Enqin YANG ; Xuehong RAN ; Minglin WANG ; Wenzheng YU ; Ruirong XU ; Zhencheng WANG ; Kehong BI ; Xin WANG ; Guoqiang LIU ; Sheng YANG ; Jin FAN ; Lingling WANG
Chinese Journal of Hematology 2014;35(5):388-392
OBJECTIVETo compare the efficacy and toxicity of the chemotherapeutic regimen containing pirarubicin and mitoxantrone on the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults.
METHODSIn this open prospective multicentre study, we randomly assigned patients with relapsed or refractory AML to receive TAE regimen (pirarubicin+cytarabine+etoposide) versus MAE regimen (mitoxantrone + cytarabine + etoposide). The efficacy and toxicity were compared between the two groups.
RESULTS56 patients entered this clinical trial. The complete remission (CR) rate on TAE arm was 79.0% versus 55.6% on MAE arm with the overall response (OR) rates of 86.8% versus 88.9%, respectively. The CR was higher on TAE arm (P=0.035) but with no significant difference between the two groups regarding the overall response (OR) rate. The regimens were well tolerated in both groups. Hematologic and non-hematologic toxicity were similar except relatively lower the mean dosage of G-CSF, red blood cells and platelets transfusion on TAE arm. No significant differences were seen between the two groups regarding the overall survival and relapse free survival rates.
CONCLUSIONTAE regimen might be an effective salvage therapy in patients with relapsed or refractory AML.
Adult ; Antineoplastic Combined Chemotherapy Protocols ; administration & dosage ; therapeutic use ; Dactinomycin ; administration & dosage ; Doxorubicin ; administration & dosage ; analogs & derivatives ; Etoposide ; administration & dosage ; Granulocyte Colony-Stimulating Factor ; administration & dosage ; Humans ; Leukemia, Myeloid, Acute ; drug therapy ; Methotrexate ; administration & dosage ; Prospective Studies ; Recurrence ; Remission Induction
6.Attention Situation of Chinese Patent Medicine for Constipation in Traditional Chinese Medicine Diagnosis and Treatment Guidelines/Consensus and National Reimbursement Drug List
Youyou ZHENG ; Xuehui WANG ; Yunru CHEN ; Mei HAN ; Hongguo RONG ; Jianping LIU ; Xing LIAO ; Zhaolan LIU
Chinese Journal of Experimental Traditional Medical Formulae 2022;28(20):135-143
ObjectiveTo evaluate the methodological quality of traditional Chinese medicine (TCM) diagnosis and treatment guidelines/consensus of constipation with Appraisal of Guidelines for Research and Evaluation Ⅱ (AGREE Ⅱ)tool, and to study the attention situation of the included Chinese patent medicines in China's National Reimbursement Drug List in the guidelines/consensus. MethodThe data of CNKI,VIP,Wanfang Data,SinoMed,PubMed and Cochrane from the inception of the databases to October 2021 were searched to collect the TCM diagnosis and treatment guidelines/consensus of constipation. Then,the diagnosis and treatment standards and recommended Chinese patent medicines were extracted. Two researchers assessed the methodological quality of the guidelines/consensus with AGREE Ⅱ tool independently. The quality of reports was evaluated by Reporting Items for practice Guidelines in HealThcare (RIGHT) Statement. The recommended Chinese patent medicines in the guidelines/consensus were compared with those in the National Reimbursement Drug List. ResultEleven consensus and 2 guidelines were included,involving 794 experts. The scores of AGREE II were clarity of presentation(59.0%),scope and purpose(44.0%),stakeholder involvement(23.1%),rigor of development (12.1%),applicability (11.1%),and editorial independence (8.3%) from high to low. Five articles were recommended at B level(recommended after revision) and 8 articles were at C level (not recommended). The average scores of RIGHT Statement were as follows:basic information (93.59%),background (57.69%),evidence (18.46%),recommendations (20.88%),review and quality assurance (19.23%),funding,declaration and management of interests (0.00%), and other information (0.00%). The included guidelines/consensus recommended a total of 27 Chinese patent medicines,among which 20 were included in the National Reimbursement Drug List,with 4 species of Class A and 16 species of Class B, accounting for 74.1% of all recommended Chinese patent medicines. Ten purgative Chinese patent medicines in the National Reimbursement Drug List were recommended by the guidelines/consensus,accounting for 50% of all purgative drugs, and 8 were not recommended. There were prescriptions for purgation, for promoting digestion and removing food stagnation, for clearing heat and purging fire,and for warming the middle and dissipating cold,Tibetan medicine and Mongolian medicine. ConclusionBy the AGREE Ⅱ assessment,the methodological quality of the TCM diagnosis and treatment guidelines/consensus of constipation included in this study needed to be improved in the future. The report quality evaluated with RIGHT Statement was low. Most drugs included in the National Reimbursement Drug List were paid attention in the TCM diagnosis and treatment guidelines/consensus of constipation. Moreover,the drugs included in the National Reimbursement Drug List could basically fulfill the clinical needs reflexed from the guidelines/consensus recommendations. However, the reasons of some drugs failing to be included in the National Reimbursement Drug List needed to be studied in the future.
7.Research on the current status of clinical trial supervision for tumor neoantigen vaccine in China
Qiang LIU ; Mengqing LU ; Hongguo HU ; Liangjiang CHEN ; Wenbing YAO
China Pharmacy 2022;33(23):2826-2830
Based on the current laws and regulations framework of China, combined with practical cases, this paper systematically and comprehensively analyzes the supervision attributes, clinical trial supervision model and existing problems of tumor neoantigen vaccine, aiming to provide reference for the construction of the supervision system of clinical trial of tumor neoantigen vaccine in China. The results showed that, at present, the clinical trials of tumor neoantigen vaccine in China adopt a dual-track supervision model: clinical trials initiated by pharmaceutical enterprises and clinical trials initiated by researchers. This supervision model lags behind the development speed of the industry, mainly in the following aspects: challenges brought by dual- track supervision; the clinical trial data initiated by researchers are not effectively connected with new drug research applications; the guiding principles of clinical trial supervision need to be improved. Relevant medical institutions, regulatory authorities and cooperative enterprises can help the development of the regulatory system for clinical trials of tumor neoantigen vaccine in China from the above aspects.
8. Efficacy and safety of IA regimen containing different doses of idarubicin in de-novo acute myeloid leukemia for adult patients
Aining SUN ; Xiaopeng TIAN ; Xiangshan CAO ; Jian OUYANG ; Jian GU ; Kailin XU ; Kang YU ; Qingshu ZENG ; Zimin SUN ; Guoan CHEN ; Sujun GAO ; Jin ZHOU ; Jinghua WANG ; Linhua YANG ; Jianmin LUO ; Mei ZHANG ; Xinhong GUO ; Xiaomin WANG ; Xi ZHANG ; Keqian SHI ; Hui SUN ; Xinmin DING ; Jianda HU ; Ruiji ZHENG ; Hongguo ZHAO ; Ming HOU ; Xin WANG ; Fangping CHEN ; Yan ZHU ; Hong LIU ; Dongping HUANG ; Aijun LIAO ; Liangming MA ; Liping SU ; Lin LIU ; Zeping ZHOU ; Xiaobing HUANG ; Xuemei SUN ; Depei WU
Chinese Journal of Hematology 2017;38(12):1017-1023
Objective:
To investigate the efficacy and safety of IA regimen which contains idarubicin (IDA) 8 mg/m2, 10 mg/m2 or 12 mg/m2 as induction chemotherapy for adult patients with de-novo acute myeloid leukemia (AML) .
Methods:
A total of 1 215 newly diagnosed adult AML patients, ranging from May 2011 to March 2015 in the First Affiliated Hospital of Soochow University and other 36 clinical blood centers in China were enrolled in the multicenter, single-blind, non-randomized, clinical controlled study. To compare the response rate of complete remission (CR) , adverse events between different dose idarubicin combined with cytarabine (100 mg/m2) as induction chemotherapy in newly diagnosed patients of adult AML.
Results:
Of 1 207 evaluable AML patients were assigned to this analysis of CR rate. The CR rates of IDA 8 mg/m2 group, IDA 10 mg/m2 group and IDA 12 mg/m2 group were 73.6% (215/292) , 84.1% (662/787) and 86.7% (111/128) , respectively (
9.Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies.
Peng LIU ; Caifang GAO ; Hongguo CHEN ; Chi Teng VONG ; Xu WU ; Xudong TANG ; Shengpeng WANG ; Yitao WANG
Acta Pharmaceutica Sinica B 2021;11(9):2798-2818
Inflammatory bowel disease (IBD) is a chronic intestinal disease with painful clinical manifestations and high risks of cancerization. With no curative therapy for IBD at present, the development of effective therapeutics is highly advocated. Drug delivery systems have been extensively studied to transmit therapeutics to inflamed colon sites through the enhanced permeability and retention (EPR) effect caused by the inflammation. However, the drug still could not achieve effective concentration value that merely utilized on EPR effect and display better therapeutic efficacy in the inflamed region because of nontargeted drug release. Substantial researches have shown that some specific receptors and cell adhesion molecules highly expresses on the surface of colonic endothelial and/or immune cells when IBD occurs, ligand-modified drug delivery systems targeting such receptors and cell adhesion molecules can specifically deliver drug into inflamed sites and obtain great curative effects. This review introduces the overexpressed receptors and cell adhesion molecules in inflamed colon sites and retrospects the drug delivery systems functionalized by related ligands. Finally, challenges and future directions in this field are presented to advance the development of the receptor-mediated targeted drug delivery systems for the therapy of IBD.